Wessex led phase III trial of new Covid-19 treatment begins

A global phase III trial of a new COVID-19 treatment, led by Professor Tom Wilkinson at the University of Southampton, has begun.

It is hoped that inhaled drug SNG001, developed at University Hospital Southampton in partnership with Synairgen, will prevent the worsening of COVID-19 in hospitalised patients.

The COVID-19 therapy enters into large-scale international trials following early phase results indicating it could prevent patients’ decline, reducing the usage of Intensive Care Units and improving recovery times.

The NIHR-supported study will recruit more than 600 participants from twenty countries. Find out more about the trial.